ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (27)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eddahibi, S.
Right arrow Articles by Adnot, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eddahibi, S.
Right arrow Articles by Adnot, S.
Eur Respir J 2002; 20:1559-1572
Copyright ©ERS Journals Ltd 2002


Pathobiology of pulmonary arterial hypertension

S. Eddahibi1, N. Morrell2, M-P. d'Ortho1, R. Naeije3 and S. Adnot1

1 INSERM U492 and Dept of Physiology, Hôpital H. Mondor, AP-HP, Créteil, France. 2 Dept of Medicine, University of Cambridge, Addenbrooke's and Papworth Hospitals, Cambridge, UK. 3 Laboratory of Physiology, Erasme University hospital, Brussels, Belgium

CORRESPONDENCE: S. Adnot, INSERM U492, Département de Physiologie, Faculté de Médecine de Créteil, 94010 Créteil, France. Fax: 33 148981777. E-mail: serge.adnot@creteil.inserm.fr

Keywords: bone morphogenic receptor-II, extracellular matrix remodelling, primary pulmonary hypertension, pulmonary vascular remodelling, serotonin transporter, smooth muscle

Received: September 2, 2002
Accepted September 9, 2002

Abstract

Recent years have witnessed important advances in the understanding of the pathophysiology of primary pulmonary hypertension (PPH). Both genetic and mechanistic studies have succeeded in identifying new molecular pathways relevant to the process of pulmonary vascular remodelling, which underlies PPH.

Mutations in the type II bone morphogenetic protein (BMP) receptor (BMPR)-II are now considered to be the genetic basis for familial PPH and ~30% of cases of sporadic PPH. The identification of the relevance of the BMP pathway to the aetiology of PPH now raises many questions about the link between the BMPR-II mutant genotype and the PPH phenotype.

As PPH does not develop in all subjects with BMPR-II mutations, environmental or associated genetic factors may play a crucial role. Among these, the finding of an association between PPH and the L-allelic variant of the serotonin transporter (5-HTT) gene indicates that 5-HTT, which controls smooth muscle hyperplasia, probably contributes to susceptibility to PPH or is an important modifier of the PPH phenotype.

Recognition of these molecular pathways should provide insight into the pathogenesis not only of primary pulmonary hypertension, but also of secondary forms of pulmonary hypertension. This should soon lead to the development of new and more selective therapeutic approaches to pulmonary hypertension.




This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
H. Syyong, C. Cheung, D. Solomon, C. Y. Seow, and K. H. Kuo
Adaptive response of pulmonary arterial smooth muscle to length change
J Appl Physiol, April 1, 2008; 104(4): 1014 - 1020.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
R. Souza, M. Humbert, B. Sztrymf, X. Jais, A. Yaici, J. Le Pavec, F. Parent, P. Herve, F. Soubrier, O. Sitbon, et al.
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
Eur. Respir. J., February 1, 2008; 31(2): 343 - 348.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. Izikki, N. Hanoun, E. Marcos, L. Savale, A. M. Barlier-Mur, F. Saurini, S. Eddahibi, M. Hamon, and S. Adnot
Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice
Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L1045 - L1052.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
H. H. Patel, S. Zhang, F. Murray, R. Y. S. Suda, B. P. Head, U. Yokoyama, J. S. Swaney, I. R. Niesman, R. T. Schermuly, S. S. Pullamsetti, et al.
Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension
FASEB J, September 1, 2007; 21(11): 2970 - 2979.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. C. Chan, P. H. Nguyen, B. N. Davis, N. Ohoka, H. Hayashi, K. Du, G. Lagna, and A. Hata
A Novel Regulatory Mechanism of the Bone Morphogenetic Protein (BMP) Signaling Pathway Involving the Carboxyl-Terminal Tail Domain of BMP Type II Receptor
Mol. Cell. Biol., August 15, 2007; 27(16): 5776 - 5789.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. R. Henkens, K. T. B. Mouchaers, H. W. Vliegen, W. J. van der Laarse, C. A. Swenne, A. C. Maan, H. H. M. Draisma, I. Schalij, E. E. van der Wall, M. J. Schalij, et al.
Early changes in rat hearts with developing pulmonary arterial hypertension can be detected with three-dimensional electrocardiography
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1300 - H1307.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
A. Zakrzewicz, F. M. Kouri, B. Nejman, G. Kwapiszewska, M. Hecker, R. Sandu, E. Dony, W. Seeger, R. T. Schermuly, O. Eickelberg, et al.
The transforming growth factor-{beta}/Smad2,3 signalling axis is impaired in experimental pulmonary hypertension
Eur. Respir. J., June 1, 2007; 29(6): 1094 - 1104.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
P. B. Sehgal, S. Mukhopadhyay, F. Xu, K. Patel, and M. Shah
Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1526 - L1542.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. E. Morty, B. Nejman, G. Kwapiszewska, M. Hecker, A. Zakrzewicz, F. M. Kouri, D. M. Peters, R. Dumitrascu, W. Seeger, P. Knaus, et al.
Dysregulated Bone Morphogenetic Protein Signaling in Monocrotaline-Induced Pulmonary Arterial Hypertension
Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1072 - 1078.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
G. Lagna, P. H. Nguyen, W. Ni, and A. Hata
BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells.
Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L1059 - L1067.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
L. Dewachter, S. Adnot, E. Fadel, M. Humbert, B. Maitre, A.-M. Barlier-Mur, G. Simonneau, M. Hamon, R. Naeije, and S. Eddahibi
Angiopoietin/Tie2 Pathway Influences Smooth Muscle Hyperplasia in Idiopathic Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., November 1, 2006; 174(9): 1025 - 1033.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. C. Tamby, M. Humbert, P. Guilpain, A. Servettaz, N. Dupin, J. J. Christner, G. Simonneau, J. Fermanian, B. Weill, L. Guillevin, et al.
Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension
Eur. Respir. J., October 1, 2006; 28(4): 799 - 807.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Ku, S. Howard, W. Ni, G. Lagna, and A. Hata
OAZ Regulates Bone Morphogenetic Protein Signaling through Smad6 Activation
J. Biol. Chem., February 24, 2006; 281(8): 5277 - 5287.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
S Ulrich, M Fischler, B Walder, T Pfammatter, and R Speich
Klippel-Trenaunay syndrome with small vessel pulmonary arterial hypertension
Thorax, November 1, 2005; 60(11): 971 - 973.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. Rondelet, F. Kerbaul, R. Van Beneden, S. Motte, P. Fesler, I. Hubloue, M. Remmelink, S. Brimioulle, I. Salmon, J.-M. Ketelslegers, et al.
Signaling Molecules in Overcirculation-Induced Pulmonary Hypertension in Piglets: Effects of Sildenafil Therapy
Circulation, October 12, 2004; 110(15): 2220 - 2225.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M.M. Hoeper and A.T. Dinh-Xuan
Combination therapy for pulmonary arterial hypertension: still more questions than answers
Eur. Respir. J., September 1, 2004; 24(3): 339 - 340.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. Naeije and S. Eddahibi
Serotonin in Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med., August 1, 2004; 170(3): 209 - 210.
[Full Text] [PDF]


Home page
Eur Respir JHome page
S.M. Kawut and H.I. Palevsky
New answers raise new questions in pulmonary arterial hypertension
Eur. Respir. J., June 1, 2004; 23(6): 799 - 801.
[Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
E. Laffon, C. Vallet, V. Bernard, M. Montaudon, D. Ducassou, F. Laurent, and R. Marthan
A computed method for noninvasive MRI assessment of pulmonary arterial hypertension
J Appl Physiol, February 1, 2004; 96(2): 463 - 468.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. Springer and A. Fischer
Substance P-induced pulmonary vascular remodelling in precision cut lung slices
Eur. Respir. J., October 1, 2003; 22(4): 596 - 601.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
B. Rondelet, R. Van Beneden, F. Kerbaul, S. Motte, P. Fesler, K. McEntee, S. Brimioulle, J-M. Ketelslegers, and R. Naeije
Expression of the serotonin 1b receptor in experimental pulmonary hypertension
Eur. Respir. J., September 1, 2003; 22(3): 408 - 412.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the European Respiratory Society.